ReviewPharmaceutics2023
Polymer-Based Nanostructures for Pancreatic Beta-Cell Imaging and Non-Invasive Treatment of Diabetes.
Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Oral GLP-1-Based Therapeutics in the Obesity-Metabolic Syndrome-Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Fiber-Electrospun Hydrogel Therapy for DNP: A synergistic electrospun-hydrogel composite for alleviating diabetic neuropathic pain via MMP9 regulation and sodium channel inhibition.Bioengineering & translational medicine · 2026Article
- Analysis of Pharmacological Properties ofLife (Basel, Switzerland) · 2025Review
- Nano-Phytomedicine: Harnessing Plant-Derived Phytochemicals in Nanocarriers for Targeted Human Health Applications.Molecules (Basel, Switzerland) · 2025Review
- Synthesis and swelling studies of modified chitosan smart hydrogels containing alkyl sulfonate anionic pendant groups as microparticles for insulin release.Scientific reports · 2025Article
- Biomaterial-based strategies for bone cement: modulating the bone microenvironment and promoting regeneration.Journal of nanobiotechnology · 2025Review
- Revolutionizing Drug Delivery: The Impact of Advanced Materials Science and Technology on Precision Medicine.Pharmaceutics · 2025Review
- Harnessing beta-cell replication: advancing molecular insights to regenerative therapies in diabetes.Frontiers in endocrinology · 2025Review
- Green synthesis and characterization of iron nanoparticles synthesized from bioflocculant for wastewater treatment: A review.Biotechnology notes (Amsterdam, Netherlands) · 2025Review
- A randomized controlled trial of Shengji ointment combined with bromelain in promoting healing of tendon-exposed diabetic foot wounds: integrated 16S rDNA sequencing and metabolomics analysis.Frontiers in pharmacology · 2025Article
- Nanostructured Lipid Carrier-Mediated Transdermal Delivery System of Glibenclamide for Gestational Diabetes: Pharmacokinetic and Pharmacodynamic Evaluation.Current drug delivery · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes poses major economic, social, and public health challenges in all countries worldwide. Besides cardiovascular disease and microangiopathy, diabetes is a leading cause of foot ulcers and lower limb amputations. With the continued rise of diabetes prevalence, it is expected that the future burden of diabetes complications, early mortality, and disabilities will increase. The diabetes epidemic is partly caused by the current lack of clinical imaging diagnostic tools, the timely monitoring of insulin secretion and insulin-expressing cell mass (beta (β)-cells), and the lack of patients' adherence to treatment, because some drugs are not tolerated or invasively administrated. In addition to this, there is a lack of efficient topical treatment capable of stopping the progression of disabilities, in particular for treating foot ulcers. In this context, polymer-based nanostructures garnered significant interest due to their tunable physicochemical characteristics, rich diversity, and biocompatibility. This review article emphasizes the last advances and discusses the prospects in the use of polymeric materials as nanocarriers for β-cell imaging and non-invasive drug delivery of insulin and antidiabetic drugs in the management of blood glucose and foot ulcers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.